One approach under investigation to improve the effectiveness of radiotherapy is the use of nanoparticles as radiosensitizers. At an ESTRO session focused on novel technologies, described the first-in-man study of gadolinium-based AGuIX nanoparticles as radiosensitizing agents. AGuIX nanoparticles, which are around 4 nm in size, are also MRI contrast agents, enabling visualization of their localization.
In a phase I study, NANO-RAD1, the researchers treated 15 patients with multiple brain metastases from melanoma, or lung, breast, or colon cancer. After intravenous injection with the nanoparticles, the patients received a 30 Gy dose of whole-brain radiotherapy in 10 fractions. The team used five AGuIX dose levels, from 15 to 100 mg/kg, to determine the maximum tolerated dose.
MR images showed that AGuIX localized in all of the metastases, regardless of primary tumor type, with no nanoparticles seen in healthy brain tissues two hours after injection. The results also revealed that the nanoparticles were safe at all dose levels. There was good immediate tolerance, no pain, no systemic reactions and no local complications.
Source: Physics World
Name of Author: Tami Freeman